Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3951-3959

  Luo, Haitao ^a   Jiang, Bingbing ^b   Li, Bingyun ^b,c,d   Li, Zhaoliang ^a   Jiang, Bing Hua ^e   Chen, Yi Charlie ^a  

^a Alderson Broaddus College   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WVNano Initiative   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Kaempferol; Nanochemoprevention; Nanoparticles; Natural compound; Ovarian cancer; Viability

Indexed keywords

CHITOSAN; KAEMPFEROL; NANOPARTICLE; POLY(ETHYLENE OXIDE)POLY(PROPYLENE OXIDE)POLY(ETHYLENE OXIDE) NANOPARTICLE; POLY(LACTIC ACID CO GLYCOLIC ACID)POLYETHYLENIMINE; POLYAMIDOAMINE; POLYGLACTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; OVARY CANCER; SURFACE CHARGE;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; KAEMPFEROLS; LACTIC ACID; NANOPARTICLES; OVARIAN NEOPLASMS; OVARY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; PROPYLENE GLYCOLS;

EID: 84870352900     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33670     Document Type: Article

References (39)

1. Gonzalez CA, Riboli E. Diet and cancer prevention: where we are, where we are going. Nutr Cancer. 2006;56:225-231.
2. Holick CN, Giovannucci EL, Rosner B, Stampfer MJ, Michaud DS. Prospective study of intake of fruit, vegetables, and carotenoids and the risk of adult glioma. Am J Clin Nutr. 2007;85:877-886.
3. Bosetti C, Rossi M, McLaughlin JK, etal. Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2007;16:98-101.
4. Hanhineva K, Törrönen R, Bondia-Pons I, etal. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci. 2010;11:1365-1402.
5. Rudkowska I, Jones PJ. Functional foods for the prevention and treatment of cardiovascular diseases: cholesterol and beyond. Expert Rev Cardiovasc Ther. 2007;5:477-490.
6. Bosetti C, Bravi F, Talamini R, etal. Flavonoids and prostate cancer risk: a study in Italy. Nutr Cancer. 2006;56:123-127.
7. Theodoratou E, Kyle J, Cetnarskyj R, etal. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:684-693.
8. Rossi M, Negri E, Lagiou P, etal. Flavonoids and ovarian cancer risk: a case-control study in Italy. Int J Cancer. 2008;123:895-898.
9. Duthie G, Crozier A. Plant-derived phenolic antioxidants. Curr Opin Clin Nutr Metab Care. 2000;3:447-451.
10. Hung H. Inhibition of estrogen receptor alpha expression and function in MCF-7cells by kaempferol. J Cell Physiol. 2004;198:197-208.
11. Sharma V, Joseph C, Ghosh S, Agarwal A, Mishra MK, Sen E. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Mol Cancer Ther. 2007;6:2544-2553.
12. Leung HW, Lin CJ, Hour MJ, Yang WH, Wang MY, Lee HZ. Kaempferol induces apoptosis in human lung non-small carcinoma cells accompanied by an induction of antioxidant enzymes. Food Chem Toxicol. 2007;45:2005-2013.
13. Cortes JR, Perez-GM, Rivas MD, Zamorano J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol. 2007;179:3881-3887.
14. Lee KM, Lee KW, Jung SK, etal. Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity. Biochem Pharmacol. 2010;80:2042-2049.
15. García-Mediavilla V, Crespo I, Collado PS, etal. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007;557:221-229.
16. Luo H, Rankin GO, Juliano N, Jiang BH, Chen YC. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem. 2012;130:321-328.
17. Luo H, Rankin GO, Li Z, DePriest L, Chen YC. Kaempferol induces apoptosis in ovarian cancer cells through activating p53in the intrinsic pathway. Food Chem. 2011;128:513-519.
18. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009;61:554-563.
19. Luo H, Jiang BH, King SM, Chen YC. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer. 2008;60:800-809.
20. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer. 2007;121:2225-2232.
21. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-171.
22. Siddiqui IA, Adhami VM, Ahmad N, Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer. 2010;62:883-890.
23. Siddiqui IA, Adhami VM, Christopher J, Chamcheu, Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomedicine. 2012;7:591-605.
24. Ma X, Wang H, Jin S, Wu Y, Liang XJ. Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. Int J Nanomedicine. 2012;7:1313-1328.
25. Ranganathan R, Madanmohan S, Kesavan A, etal. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine. 2012;7:1043-1060.
26. Sabnis N, Nair M, Israel M, McConathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine. 2012;7:975-983.
27. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600-1603.
28. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
29. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol. 2007;2:203-204.
30. Siddiqui IA, Adhami VM, Bharali DJ, etal. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009;69:1712-1716.
31. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
32. Banks E. The epidemiology of ovarian cancer. In: Bartlett JMS, editor. Ovarian Cancer: Methods and Protocols. Totawa, NJ: Humana Press Inc; 2000.
33. Antoniou A, Pharoah PDP, Narod S, etal. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
34. Guterres SS, Fessi H, Barrat G, Puisieux F, Devissaguet JP. Poly(D, L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm Res. 1995;12:1545-1547.
35. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688-701.
36. Myc A, Kukowska-Latallo J, Cao P, etal. Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo. Anticancer Drugs. 2010;21:186-192.
37. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21:797-802.
38. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131-135.
39. Sunoqrot S, Bae JW, Pearson RM, etal. Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. Biomacromolecules. 2012;13:1223-1230.